Navigation Links
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Date:12/15/2007

affected breast after preoperative administration of Xeloda and Taxotere for HER2-negative patients and in combination with Herceptin for HER2-positive patients. Secondary endpoints included safety profile; quality of life; local recurrence; disease-free survival; distant disease-free survival; and overall survival. Other secondary endpoints included pCR in sentinel and axillary, or underarm, lymph nodes; clinical response rate; ability of blood and tissue markers; genomic profiling of the tumors; circulating tumor cells for HER2-neu positive patients; and p53 gene mutations to predict short-term clinical and pathological responses.

Study participants were limited to female outpatients, aged 18 and older, who were diagnosed with HER2-negative or HER2-positive breast cancer, with no evidence of metastatic disease except ipsilateral axillary lymph nodes, or axillary lymph nodes found on the same side of the body, and no prior history of treatment.

Patients received four three-week cycles of the treatment regimen. HER2-negative patients received Xeloda 825 mg/m2 twice a day for 14 days with seven days off, and also received Taxotere 75 mg/m2 IV on the first day. HER2-positive patients were on the same regimen, but also received Herceptin each week with a loading dose of 4 mg/kg for 90 minutes followed by 2 mg/kg for 30 minutes for a total of 12 weeks before definitive surgery.

The most frequent adverse events (AEs) were hematologic toxicities and hand-foot syndrome. Five HER2-neu negative patients and one HER2-positive patient experienced progression before surgery. There were no treatment- related deaths prior to surgery, nor were there clinical or subclinical cardiac events.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill form, Xeloda is enzymatically activated within the body; when it comes into contact with a naturally
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
2. Promising drug combination may help those with ocular melanoma that has spread
3. Combination therapy reverses effects of portal hypertension in rats
4. Combination vaccines okay for infants, study shows
5. Antidepressants and painkillers - a dangerous combination
6. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
7. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
8. Drug combination might offer hope for patients deadly brain tumors
9. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
10. Combination targets: some drugs may work best when they work together
11. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... More states are passing legislation permitting or requiring schools ... child having a severe allergic reaction. Epinephrine auto-injectors ... that can lead to throat swelling, breathing difficulties, a ... In people with severe allergies to certain foods, ... certain drugs, anaphylaxis can occur within moments of exposure ...
(Date:9/19/2014)... Wisconsin (MCW) scientists has identified a new gene associated with ... humans. The findings are published in the September issue of ... Ph.D., associate professor of pediatrics at MCW and a researcher ... study and is the corresponding author of the paper. , ... in which a variant was associated with fasting glucose levels ...
(Date:9/19/2014)... September 19, 2014 BCC Research reveals ... AND GLOBAL MARKETS , the global market for human ... billion by 2018, with a five-year compound annual growth ... is growing at a steady 3.8% CAGR. , Given ... lower sales, coupled with the incidence of increasing mortality ...
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 Ticket ... presale tickets for her 2015 “Honeymoon” Tour. This ... ARIANA-2015 for additional savings at the checkout. , Ariana Grande ... MO (Independence Event Center) , Feb. 28, 2015: Milwaukee, WI ... MN (Xcel Energy Center) , March 03, 2015: Chicago, IL ...
(Date:9/19/2014)... from the wonder material graphene has been used to ... cancer. , The biosensor has been shown to ... tests currently in use, and was able to provide ... possibility of a rapid, point-of-care diagnostic tool for patients. ... in IOP Publishing,s journal 2D Materials . , ...
Breaking Medicine News(10 mins):Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 2Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 3Health News:Ariana Grande Tickets in Miami, Philadelphia, Chicago, Saint Paul, Fairfax, Uncasville, Orlando, San Jose, New York, Detroit, San Antonio, Pittsburgh, Atlanta & Dallas 4Health News:Graphene sensor tracks down cancer biomarkers 2
... and public campaigner, has made known the fact that she ... , Dame Anita known worldwide for her company, ... was infected with the virus in 1971 via infected blood, ... businesswoman who is well known for her indefatigable campaigning has ...
... Organization (PAHO) are working with health authorities in Paraguay ... has affected a// number of communities throughout the nation ... America. ,PAHO officials warn that the entire ... prepare for what promises to be a "difficult year" ...
... A recent study by scientists at University of Wisconsin-Madison ... hear better. ,Led by Ruth Litovsky, an ... suggests that deaf children who have a cochlear implant ... use both implants instead of one. Children with two ...
... treatment for an abdominal aortic aneurysm, a weak spot ... time. If the vessel ruptures suddenly before surgery to ... scientists say they have identified a key enzyme that ... growth of aneurysms. Their finding raises hopes for developing ...
... omega-3 fatty acids on their own can alleviate depression, ... there is only limited evidence that they can relieve ... adds. ,Evidence from circumstantial research has suggested ... such as depression. And the findings have attracted widespread ...
... bottle-fed children, reveals a large, long term study, published// ahead ... ,Over 3000 children from 16 rural and urban areas ... of the Boyd Orr Study of Diet and Health in ... on 1414 people in their 60s and 70s, for whom ...
Cached Medicine News:Health News:Body Shop Founder’s New Project-against Hepatitis 2Health News:PAHO Urges Readiness for Dengue Outbreaks in 2007 2Health News:Cochlear Implants in Both Ears Enables Better Hearing 2Health News:Cochlear Implants in Both Ears Enables Better Hearing 3Health News:Enzyme Critical for Early Growth of Abdominal Aortic Aneurysms 2Health News:Enzyme Critical for Early Growth of Abdominal Aortic Aneurysms 3
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... 30, 2014. Quarter Ended June 30, ... 2014 increased $492,000, or 18%, to $3.2 million from ... 2013, due primarily to an increase of $746,000 in ... largest customer, partially offset by an aggregate decrease in ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13
... Terumo Heart, Inc. announced,today that it ... the European,Association of Cardio-Thoracic Surgeons (EACTS) meeting ... ) (Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO ) ... Trial results for the DuraHeart(TM),Left Ventricular Assist ...
... analysis reported,at the American Society for Bone and ... decreased clinical fracture risk by 50% over,three years ... women with,osteoporosis who had suffered a previous hip ... evaluated the combined incidence,of vertebral and nonvertebral clinical ...
Cached Medicine Technology:Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 2Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 3Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture 4
Reusable, stainless steel trephine with handle....
Reusable, stainless steel trephine with handle....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Medicine Products: